High-resolution computed tomography (HRCT) of the chest in axial view at two different levels (A: upper/mid-thorax, B: lung bases). The images demonstrate bilateral, symmetric pulmonary abnormalities characteristic of a usual interstitial pneumonia (UIP) pattern. Key findings include prominent reticular opacities and peripheral, subpleural honeycombing, particularly evident in the subpleural regions of both lungs. There is a clear predilection for the proximal pleural parts and the lung bases, with relative sparing of the more central lung parenchyma. No significant ground-glass opacities, consolidations, or exudative changes are observed. The presence of these structural alterations—specifically honeycombing and architectural distortion—is highly suggestive of chronic fibrosing interstitial lung disease, such as idiopathic pulmonary fibrosis (IPF). These findings are essential for medical learners to recognize the diagnostic hallmarks of UIP on CT imaging.

This composite educational resource consists of a diagnostic imaging panel (A) and a comparison bar chart (B) illustrating interstitial lung disease (ILD) patterns in patients with Sjögren's syndrome. Panel A displays axial High-Resolution Computed Tomography (HRCT) slices of four distinct ILD patterns: Usual Interstitial Pneumonia (UIP) characterized by peripheral reticulation and honeycombing; Non-Specific Interstitial Pneumonia (NSIP) showing more uniform ground-glass opacities; Desquamative Interstitial Pneumonia (DIP) with diffuse ground-glass attenuation; and Combined Pulmonary Fibrosis and Emphysema (CPFE) demonstrating upper-lobe emphysematous lucencies alongside fibrotic changes. Panel B is a horizontal bar chart quantifying the prevalence of these CT disease patterns among the study cohort. The chart indicates that UIP is the most frequent pattern, followed by NSIP, unspecific changes (Unspez), and lastly DIP and CPFE, which show equal, lower prevalence. This visual aid is intended for medical education regarding the radiologic classification and epidemiological distribution of pulmonary manifestations in systemic autoimmune diseases.

This composite diagnostic image displays four axial slices (A, B, C, D) of a high-resolution computerized tomography (HRCT) scan of the chest, illustrating a Usual Interstitial Pneumonia (UIP) pattern in a patient with Idiopathic Pulmonary Fibrosis (IPF). The scans demonstrate a classic subpleural and basal predominant distribution of interstitial lung disease. Key radiological features include: (A) early peripheral reticular opacities; (B and C) prominent traction bronchiectasis, characterized by the irregular dilation of bronchioles due to surrounding parenchymal fibrosis; and (D) extensive honeycombing, visible as clustered, thick-walled cystic airspaces in the subpleural regions of the lung bases. These findings collectively indicate advanced pulmonary fibrosis with architectural distortion. The image serves as an educational tool for identifying the hallmark CT characteristics of a UIP pattern, essential for the diagnosis of IPF and its differentiation from other interstitial lung diseases in a clinical pulmonology and radiology context.

This composite educational image includes a clinical flowchart and two high-resolution computed tomography (HRCT) axial slices of the chest, illustrating the progression from stable Idiopathic Pulmonary Fibrosis (IPF) to an Acute Exacerbation (AE-IPF). Panel A presents a study flowchart detailing the selection process of 26 patients with AE-IPF from a cohort of 1,494 patients with interstitial lung disease (ILD). Panel B displays an axial HRCT scan showing classic features of Usual Interstitial Pneumonia (UIP) associated with stable IPF, including peripheral-predominant reticular opacities, traction bronchiectasis, and subpleural honeycombing. Panel C shows the same patient during an acute exacerbation. In addition to the pre-existing fibrotic changes seen in Panel B, there is now diffuse, bilateral ground-glass opacities (GGO), representing the hallmark radiological sign of acute alveolar damage superimposed on chronic fibrosis. This comparison highlights the key diagnostic imaging criteria for AE-IPF, essential for pulmonology and radiology education.

Summary : This flowchart outlines the treatment algorithm for idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD), specifying treatment options based on disease severity and progression risk. flowchart: # Nodes : • No indication for treatment (rectangle) • Any IIM-ILD (rectangle) • High risk of progression and/or severe multiorgan involvement (rectangle) • Progressive pulmonary fibrosis (rectangle) • Rapidly progressive ILD over weeks to few months (rectangle) • Immunosuppressive treatment (rectangle, green background) • Glucocorticoids (rectangle, green background) • CNI, rituximab (rectangle, green background) • Mycophenolate, Azathioprine (rectangle, white background) • Combination therapy with high-dose glucocorticoids, cyclophosphamide, rituximab, CNI and IVIG (rectangle, blue background) • Nintedanib, combination of immunosuppressant and nintedanib (rectangle, blue background) • Combination therapy with high-dose glucocorticoids and cyclophosphamide or rituximab with CNI; IVIG, JAK inhibitors, plasmapheresis may be considered (rectangle, blue background) • Monitoring (rectangle, bottom row) # Connectors : • Flow is left to right, starting from "No indication for treatment" and "Any IIM-ILD" to more severe categories. • "Any IIM-ILD" leads to "Immunosuppressive treatment," which branches to "Glucocorticoids," "CNI, rituximab," and "Mycophenolate, Azathioprine." • "High risk of progression and/or severe multiorgan involvement" leads to "Combination therapy with high-dose glucocorticoids, cyclophosphamide, rituximab, CNI and IVIG." • "Progressive pulmonary fibrosis" leads to "Nintedanib, combination of immunosuppressant and nintedanib." • "Rapidly progressive ILD over weeks to few months" leads to "Combination therapy with high-dose glucocorticoids and cyclophosphamide or rituximab with CNI; IVIG, JAK inhibitors, plasmapheresis may be considered." • All treatment pathways converge to "Monitoring" at the bottom. # Layout : • Horizontal arrangement of disease severity categories from left (mild/no indication) to right (rapidly progressive). • Treatment options are layered below each severity category. • Monitoring is a unified bar at the bottom, spanning all categories. # Analysis : • The flowchart provides a stepwise escalation of therapy based on disease severity, starting with immunosuppressive agents for all IIM-ILD, progressing to combination and advanced therapies for high-risk or rapidly progressive cases. • Monitoring is emphasized as a universal step regardless of treatment pathway. • The use of color highlights the escalation from standard immunosuppressive therapy (green) to more aggressive or adjunctive therapies (blue) as disease severity increases.